RX-0301 is under clinical development by Zhejiang Haichang Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RX-0301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RX-0301 overview

RX-0301 is under development for treatment of hepatocellular carcinoma. It is a nano-liposomal formulation of RX-0201. The drug candidate targets Akt-1 and is developed based on QTsome technology.

Zhejiang Haichang Biotechnology overview

Zhejiang Haichang Biotechnology is a biotechnology company headquartered in China. The company is engaged in the manufacture and development of complex intravenous pharmaceutical products for the treatment of cancer related diseases

For a complete picture of RX-0301’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.